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Viruses exploit different strategies to escape immune surveillance, including the introduction of mutations
in cytotoxic T-lymphocyte (CTL) epitopes. The sequence of these epitopes is critical for their binding to major
histocompatibility complex (MHC) class I molecules and recognition by specific CTLs, both of which inter-
actions may be lost by mutation. Sequence analysis of the nucleoprotein gene of influenza A viruses (H3N2)
isolated in The Netherlands from 1989 to 1999 revealed two independent amino acid mutations at the anchor
residue of the HLA-B27-specific CTL epitope SRYWAIRTR (383 to 391). A R384K mutation was found in
influenza A viruses isolated during the influenza season 1989–1990 but not in subsequent seasons. In the
influenza season 1993–1994, a novel mutation in the same CTL epitope at the same position was introduced.
This R384G mutation proved to be conserved in all influenza A viruses isolated from 1993 onwards. Both
mutations R384K and R384G abrogated MHC class I presentation and allowed escape from recognition by
specific CTLs.
Cytotoxic T lymphocytes (CTLs) of the CD81 phenotype
control viral infections by recognizing antigenic peptides of
viral proteins presented by infected cells in association with
major histocompatibility complex (MHC) class I molecules.
The interaction of specific CTLs with these complexes may
lead to the elimination of infected cells. Viruses exploit several
strategies to escape from immune surveillance by CTLs (20,
31). One strategy involves the introduction of amino acid mu-
tations within CTL epitopes or in sequences flanking these
epitopes. The flanking sequences are important for cytosolic
processing of the viral proteins to yield the CTL epitopes,
usually 9-mer peptides, while the epitope sequences them-
selves are critical both for association with MHC class I mol-
ecules and for recognition by virus-specific CTLs. Mutations
within or in close proximity to CTL epitopes, therefore, may be
accompanied by loss of CTL-mediated lysis of target cells (14,
46). In addition, mutations in CTL epitopes may generate
peptides that antagonize CTL function (2, 10, 17, 19, 37).
Mutations that affect CTL epitopes, resulting in escape from
immune surveillance by specific CTLs, have been described for
several viruses causing persistent infections, including lympho-
cytic choriomeningitis virus (27, 34), Epstein-Barr virus (1, 4, 7,
8), human immunodeficiency virus (HIV) (6, 13, 20, 26, 33, 36),
hepatitis B virus (3), and hepatitis C virus (45).
Influenza A viruses, causing acute infections, continuously
escape from recognition by virus-neutralizing antibodies as a
result of accumulation of mutations in their surface glycopro-
teins hemagglutinin and neuraminidase (antigenic drift) or by
introduction of new subtypes of these glycoproteins (antigenic
shift). The more conserved internal proteins of influenza vi-
ruses, such as the nucleoprotein (NP) and the matrix protein
are important targets for CTLs (12, 24). Mutations in these
proteins, which occur less frequently than in the surface gly-
coproteins, potentially could affect CTL-mediated immune
surveillance.
Here we show that mutations at the anchor residue of the
HLA-B27-restricted CTL epitope SRYWAIRTR (383 to 391),
found in the NP of influenza A (H3N2) viruses isolated be-
tween 1989 and 1999 in The Netherlands, abrogate MHC class
I presentation and recognition by specific CTLs.
MATERIALS AND METHODS
RNA isolation, RT-PCR, and sequencing. RNA of 59 influenza A (H3N2)
viruses of the influenza season 1989–1990, 16 of the season 1991–1992, 16 of the
season 1992–1993, 56 of the season 1993–1994, and 15 of the season 1998–1999
(arbitrarily chosen) obtained from the Dutch National Influenza Centre origi-
nating from geographically distinct areas in The Netherlands was isolated using
a high-pure RNA isolation kit (Boehringer Mannheim) and dissolved in 50 ml of
diethylpyrocarbonate-treated H2O. The RNA was used as template to multiply
all eight gene segments in a reverse transcriptase PCR (RT-PCR) using a single
primer set. The RT-PCR mixture contained 5 ml of RNA, 10 pmol of M13-uni12
primer (CAGGAAACAGCTATGACCAGCAAAAGCAGG), 10 pmol of M13-
uni13 primer (TGTAAAACGACGGCCAGTAGTAGAAACAAGG), 0.01 M
dithiothreitol, 0.25 mM deoxynucleoside triphosphates (dNTPs), 10 U of RNasin
(Promega), 8 U of avian myeloblastosis virus RT (Promega), and 1.25 U of Pfu
polymerase (Stratagene) in a total of 25 ml of 13 Pfu polymerase buffer. The
mixture was incubated for 60 min at 42°C followed by 4 min at 95°C, 2 min at
37°C, and 3 min at 72°C and 19 cycles of incubation for 1 min at 95°C, 1 min at
50°C, and 3 min at 72°C. The resulting cDNAs were used as template in an
NP-specific PCR (nucleotides [nt] 696 to 1243). One microliter of template was
added to 25 ml of reaction mixture containing 5 pmol of NP696 primer (TGCT
TATGAGAGAATGTGCAA), 5 pmol of NP1243 primer (TCTGTTGGTTGG
TGTTTCCTCC), 1.5 mM MgCl2, 20 mM dNTPs, and 2.5 U of Taq polymerase
(Promega) in a total of 25 ml of 13 Taq polymerase buffer. The mixture was
incubated for 2 min at 95°C followed by 1 min at 50°C and 3 min at 72°C and 29
cycles of incubation for 1 min at 95°C, 30 s at 50°C, and 3 min at 72°C. Amplified
DNA was diluted 1:5, and 10 ml was added to 10 ml of sequencing reaction
mixture (DYEnamic ET terminator cycle sequencing premix kit; Amersham
Pharmacia Biotech, Inc.) containing 10 pmol of NP696 primer. The resulting
mixture was incubated for 30 s at 95°C, 15 s at 45°C, and 2 min at 60°C for a total
of 30 cycles. Then, 2 ml of 3 M NaAc (pH 4.8) and 80 ml of absolute ethanol were
added followed by incubation on ice for 15 min and centrifugation at 2,400 3 g
for 30 min. Pellets were resuspended in 3 ml of sample buffer, and 0.8 ml was
loaded onto a sequence gel followed by automatic sequencing (ABI sequencer).
Phylogenetic analysis was performed using DNAML software (Phylip version
3.5).
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Isolation and analysis of NP-specific CTL clones. In round-bottomed micro-
titer plates, 1,000 peripheral blood mononuclear cells (PBMCs) of a selected
donor (HLA-A01, A03, B07, B2705, Cw02, or Cw07) were stimulated twice, with
an interval of 1 week, with 2.5 3 104 gamma-irradiated (30 min, 3,000 rads)
autologous phytohemagglutinin-stimulated PBMCs pulsed with the peptide
SRYWAIRTR (an HLA-B27-restricted CTL epitope of the influenza A virus NP
[amino acids (aa) 383 to 391]). The cells were cultured in RPMI 1640 medium
containing L-glutamine (2 mM), streptomycin (100 mg/ml), penicillin (100 IU/
ml), 2-mercaptoethanol (2 3 1025 M), interleukin-2 (50 U/ml), and 10% pooled
human serum at 37°C and 5% CO2. One week after the second stimulation,
expanded cells were analyzed for peptide-specific CTL activity. Cells from wells
showing CTL activity were cloned by limiting dilution (0.3, 1, and 3 cells per well)
and stimulated nonspecifically by adding 3 3 104 APD B-lymphoblastoid cell line
(B-LCL) cells, 3 3 104 BSM B-LCL cells, and 6 3 105 allogeneic PBMCs (which
were all gamma irradiated); 1 mg of phytohemagglutinin and 50 U of interleu-
kin-2 per ml (44). After incubation for 2 weeks, clones showing CTL activity were
stimulated specifically with gamma-irradiated peptide-pulsed autologous PBMCs.
After incubating the clones for 12 days, they were stimulated nonspecifically as
described above in 75-cm2 flasks. After 2 weeks, cells were harvested, aliquoted,
and stored at 2135°C until use. These CTLs will be referred to as the NP/B27
CTL clone. An HLA-A3-restricted CTL clone specific for the influenza A virus
NP epitope ILRGSVAHK (aa 265 to 273) was kindly provided by W. Biddison,
National Institutes of Health (NIH), Bethesda, Md., and will be referred to as
the NP/A3 CTL clone. The phenotype of both CTL clones was determined by
fluorescence-activated cell sorting (FACS) analysis using monoclonal antibodies
specific for CD3, CD4, and CD8, and their specificity and HLA restriction were
confirmed in CTL assays. To this end, 106 cells of an Epstein-Barr virus-trans-
formed B-LCL of an HLA-A3- and -B27-positive donor and mismatched (HLA-
A3- and -B27-negative) B-LCL cells were incubated with the peptide ILRGS-
VAHK or SRYWAIRTR (10 mM) for 1 h at 37°C and used as target cells in CTL
assays with the respective CTL clones as effectors.
Preparation of target cells. B-LCL cells (106) of one donor (HLA-A3 and
-B27 positive) were incubated with the peptide ILRSGVAHK (HLA-A3), SRY
WAIRTR (HLA-B27), or SKYWAIRTR or SGYWAIRTR (HLA-B27 mutant
peptide) at a concentration giving the highest specific lysis (10 mM for the
ILRGSVAHK peptide and 1 mM for the SRYWAIRTR and mutant peptides).
In addition, the same B-LCL cells were infected with recombinant vaccinia
viruses (RVV) expressing the NP of influenza virus A/Puerto Rico/8/34;H1N1
(A/PR/8/34) (kindly provided by B. Moss, NIH), A/Netherlands/018/94;H3N2
(A/Neth/18/94) (generated essentially as previously described [38]), or a control
vaccinia virus (VSC65), each at a multiplicity of infection of 10. Also, B-LCL
cells were infected with the influenza A virus A/PR/8/34; A/Netherlands/651/89;
H3N2 (A/Neth/651/89), having an R384K mutation; or A/Neth/18/94, having an
R384G mutation in the NP gene. Cells were cultured in RPMI 1640 medium
containing L-glutamine (2 mM), streptomycin (100 mg/ml), penicillin (100 IU/
ml), and 10% fetal bovine serum at 37°C and 5% CO2. After 16 h of incubation,
cells were washed and used as target cells in CTL assays with the NP/A3 and
NP/B27 CTL clones as effector cells.
CTL assays. Target cells (B-LCL cells) were labeled for 1 h with 75 mCi of
Na2[51Cr]O4 in RPMI 1640 medium. Cells were washed three times in culture
medium (see above) and resuspended in this medium at a concentration of 104
cells/50 ml. Effector cells (CTLs) were suspended in this medium at a concen-
tration of 2.5 3 104, 5 3 104, or 1 3 105 cells/100 ml (effector-to-target [E:T]
ratios, 2.5:1, 5:1, and 10:1). Fifty microliters of target cells was incubated either
with 100 ml of medium (spontaneous release), with 100 ml of 10% Triton X-100
(maximum release), or with 100 ml of effector cells (experimental release) for 4 h
at 37°C. Supernatants were harvested, and radioactivity was measured by gamma
counting. The percentage of specific lysis was calculated as 100 3 (experimental
release 2 spontaneous release)/(maximum release 2 spontaneous release). CTL
assays were performed in triplicate per target per E:T ratio.
Functional analysis of wild-type and mutant NP. The NP coding sequences of
influenza virus A/Hong Kong/2/68;H3N2 (A/HK/2/68), representing wild-type
virus, and A/Neth/18/94 (R384G mutant) were amplified by PCR using pBlue-
script plasmids containing the NP genes of both viruses as templates with a NotI
forward primer, CAGCGGCCGCATGGCGTCCCAAGGC, and an XhoI re-
verse primer, CACTCGAGTTAATTGTCGTACTCCTCTGC (restriction endo-
nuclease recognition sequences are underlined, and start and stop codons of the
NP gene are in boldface). PCRs were performed with 10 ng of plasmid DNA, 10
pmol of each of the primers, 1.5 mM MgCl2, 20 mM dNTPs, and 5 U of Pfu
polymerase in a total of 100 ml of 13 Pfu polymerase buffer. This mixture was
heated for 3 min at 94°C followed by a total of 20 cycles consisting of 1 min at
94°C, 2 min at 50°C, and 4 min at 72°C. The PCR products were cloned as
NotI-XhoI fragments in a modified version of the eukaryotic expression plasmid
pcDNA3 (Invitrogen) followed by large-scale production of plasmid DNA and
purification by CsCl gradient centrifugation according to standard methods.
The respective plasmids were used for transfection into 293T cells. Plasmid
DNA (1.5 mg) was mixed with equal amounts of the plasmids pHMG-PB1,
pHMG-PB2, and pHMG-PA (encoding the polymerase proteins PB1, PB2, and
PA, respectively; kindly provided by P. Palese, Mount Sinai School of Medicine,
New York, N.Y. [35]) and 0.5 mg of plasmid RF419 (constructed essentially as
described previously [29]), from which the green fluorescent protein (GFP) gene
flanked with the influenza A virus noncoding region of the NS gene segment is
transcribed in a negative orientation. This plasmid mixture was transfected into
293T cells as described previously (32). One day after transfection, cells were
subjected to FACS analysis. Cells transfected with plasmid pcDNA3 without
cloned NP sequences served as a negative control, while cells transfected with
plasmid pEGFP-N1 (encoding enhanced GFP; Clontech) served as a positive
control.
Nucleotide sequence accession numbers. Nucleotide sequences have been
submitted to GenBank and can be retrieved by the following accession numbers:
AF225709 to AF225764 (influenza season 1993–1994), AF225765 to AF225823
(influenza season 1989–1990), AF225824 to AF225839 (influenza season 1991–
1992), AF225840 to AF225855 (influenza season 1992–1993), and AF225856 to
AF225869 and AF226872 (influenza season 1998–1999).
RESULTS
NP gene sequences of influenza A (H3N2) viruses. Sequence
analysis of the NP genes of influenza A (H3N2) viruses isolated
in The Netherlands from 1989 to 1999 was performed. The
region of the NP genes sequenced encompasses aa 240 to 391
(or nt 720 to 1175) and harbors four previously described CTL
epitopes: aa 265 to 273, aa 338 to 347, aa 380 to 388, and aa 383
to 391, presented by HLA-A3, -B37, -B8, and -B27 molecules,
respectively (9, 15, 25, 42). As shown in Table 1, differences in
the nucleotide sequences of viruses isolated in the same season
were observed. Overall, 46 different nucleotide sequences were
identified in 162 viruses isolated from 1989 to 1999. Neverthe-
less, within one season viruses were closely related, as is shown
in the maximum likelihood tree in Fig. 1. The amino acid
sequences found in the influenza A viruses isolated in the
respective influenza seasons are shown in Fig. 2, and nucleo-
tide mutations underlying differences in these amino acid se-
quences are shown in Table 2. Eleven different amino acid
sequences were identified, and phylogenetic analysis based on
these amino acid sequences revealed essentially the same dis-
tances between the recent influenza virus isolates (1993 to
1998) and older isolates (Fig. 1). In the influenza season 1989–
1990, 13 out of 59 isolated viruses had an R384K mutation
affecting both the HLA-B8 and HLA-B27 epitopes (Fig. 2). In
fact, R384 is the anchor residue of the HLA-B27 epitope and
critical for association with MHC class I molecules. This
R384K mutation was not found in subsequent seasons. How-
ever, in the season 1993–1994, a novel mutation at the same
position in these CTL epitopes was found. This R384G muta-
tion was present in all 56 viruses tested of this season and
maintained in all viruses tested of the 1998–1999 season (Fig.
2). In all mutant viruses, the G at position 384 was coded for by
the same codon (Table 2). The abrupt introduction of the
R384G mutation in 1993–1994 was accompanied by two other
amino acid mutations in the sequenced NP region, S259L and
E375G. These mutations are located in close proximity to the
HLA-A3 and the HLA-B8 and HLA-B27 epitopes, respec-
tively (Fig. 2). We also sequenced several viruses isolated be-
tween 1994 and 1998 which all showed the R384G, S259L, and
E375G mutations (data not shown). In contrast to the over-
lapping HLA-B8 and HLA-B27 epitopes, the HLA-A3 epitope
ILRGSVAHK (aa 265 to 273) proved to be conserved. Only
three silent mutations were found in this epitope in 3 out of the
162 viruses tested (data not shown). Likewise, no mutations
were found that affected the HLA-B37 epitope (338 to 347).
Recognition of influenza A virus NP by specific CTL clones.
An HLA-B27-restricted CTL clone, designated NP/B27, with
specificity for the NP epitope SRYWAIRTR (aa 383 to 391),
was generated. This CTL clone lysed matched target cells,
pulsed with peptide SRYWAIRTR (Fig. 3B and D). As a
control, an HLA-A3-restricted CTL clone, designated NP/A3,
with specificity for the conserved NP epitope ILRGSVAHK
(aa 265 to 273) was used. As shown in Fig. 3A and C, this CTL
clone lysed matched target cells pulsed with the corresponding
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peptide. The phenotype of both CTL clones as determined by
FACS analysis was CD31 CD42 CD81 (data not shown).
The effect of the R384K and R384G mutations in the HLA-
B27-specific NP epitope SRYWAIRTR on CTL-mediated lysis
was first studied with synthetic peptides. The NP/B27 CTL
clone lysed target cells pulsed with the peptide SRYWAIRTR,
whereas control untreated target cells or cells pulsed with the
mutant peptide SKYWAIRTR or SGYWAIRTR were not
recognized by this CTL clone (Fig. 4B). Next, cells infected
with influenza A viruses having the respective mutations in the
NP were used as target cells. Target cells infected with influ-
enza virus A/PR/8/34, A/Neth/651/89, or A/Neth/18/94 were all
recognized by the NP/A3 CTL clone (Fig. 4E). However, the
NP/B27 CTL clone lysed only target cells infected with influ-
enza virus A/PR/8/34, which had the nonmutated epitope, and
failed to recognize target cells infected with influenza virus
A/Neth/651/89 or A/Neth/18/94, which had the R384K or the
R384G mutation, respectively (Fig. 4F). These data were fur-
ther confirmed using RVV expressing the NP of A/PR/8/34
(nonmutated epitope) or A/Neth/18/94 (R384G mutant epi-
tope). The NP/A3 CTL clone recognized target cells infected
with RVV expressing NP of A/PR/8/34 or A/Neth/18/94
equally well and failed to recognize target cells infected with a
control vaccinia virus (Fig. 4C). The NP/B27 CTL clone, how-
ever, recognized target cells infected with RVV expressing NP
of A/PR/8/34 but failed to recognize target cells infected with
RVV expressing NP of A/Neth/18/94 (Fig. 4D).
Functional analysis of NP sequences. In order to determine
whether the R384G mutation affected the function of the NP,
a eukaryotic expression plasmid encoding the NP of A/HK/
2/68 (having an R at position 384) or the NP of A/Neth/18/94
(having a G at position 384) was cotransfected with expression
plasmids encoding the three polymerase proteins of influenza
A virus (PB1, PB2, and PA) and a plasmid expressing GFP
RNA in the context of an influenza A virus NS gene segment.
Others have shown previously that such negative-sense RNA
molecules can serve as templates for production of cRNA and
mRNA in the presence of functional NP and polymerase pro-
teins, ultimately resulting in synthesis of the encoded protein
(28). GFP synthesis was measured by FACS analysis (Table 3).
The percentage of positive cells and mean fluorescence did not
differ significantly between cells transfected with the NP gene
of A/HK/2/68 and those transfected with the NP gene of
A/Neth/18/94, indicating that both NPs were equally func-
tional. Furthermore, influenza viruses A/HK/2/68 and A/Neth/
18/94 yielded comparable virus titers in MDCK cells, indicat-
ing that both viruses replicated equally well (data not shown).
DISCUSSION
In the present paper, we show that an R384K or R384G
mutation in the HLA-B27-specific epitope SRYWAIRTR (383
to 391) of influenza A virus NP abrogates MHC class I pre-
sentation and recognition by specific CTLs. In peptides that
associate with HLA-B27, the second residue is often an argi-
nine (R), and this so-called anchor residue is critical for bind-
ing to HLA-B27 molecules (18, 22, 23, 40, 43). Mutations at
this position are accompanied by loss of binding to HLA-B27
and hence loss of the activity of specific CTLs. This has pre-
viously been demonstrated for the CTL epitope KRWIIL
GLNK (263 to 272) in the HIV type 1 (HIV-1) Gag protein:
exchanging R264 for K or G diminished binding to HLA-B27
and lysis of peptide-pulsed target cells, with the R264G muta-
tion having the greatest effect (30). We here show that cells
pulsed with mutant peptides, having identical mutations at the
anchor residue of the epitope SRYWAIRTR of the influenza
A virus NP (see Table 4 for comparison), were not lysed by
HLA-B27-restricted CTLs. In addition, we show that cells in-
fected either with influenza A viruses or with vaccinia virus
expressing mutant NP were no longer recognized by specific
CTLs.
The R384K mutation was found in several isolates of the
influenza season 1989–1990, but not in later seasons. This
mutation was previously found in two viruses isolated in 1971
and 1972 (41). In contrast, the R384G mutation was found in
all influenza A virus isolates from the influenza season 1993–
1994 onwards. A search in the influenza virus sequence data-
TABLE 1. Virus variants and number of each variant
observed per influenza seasona
Season (n) Variantb No. of variant
1989–1990 (59) 1 18
2 14
3 8
4 7
5 3
6 1
7 1
8 1
9 1
10 1
11 1
12 1
13 1
14 1
1991–1992 (16) 15 8
16 3
17 3
18 1
19 1
1992–1993 (16) 20 7
21 4
22 1
23 1
24 1
25 1
26 1
1993–1994 (56) 27 35
28 3
29 2
30 2
31 2
32 1
33 1
34 1
35 1
36 1
37 1
38 1
39 1
40 1
41 1
42 1
43 1
1998–1999 (15) 44 11
45 3
46 1
a The nucleotide sequence of the NP gene (nt 720 to 1175) of each virus of a
particular season was compared to the consensus sequence of that season.
b Variant numbers correspond with the numbers shown in Fig. 1.
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base (Los Alamos National Laboratory) and in the literature
revealed that from the introduction of H3N2 viruses in 1968
until the 1993 epidemics, all virus isolates (except for the
R384K mutant viruses mentioned above) had the nonmutated
HLA-B27 epitope SRYWAIRTR. Since most viruses have
been selected for sequencing based on antigenic properties of
their hemagglutinin, we assume that the NP sequences of in-
fluenza viruses in this database are random with regard to CTL
epitopes. Of note, the R384G mutation has never been found
in H1N1 and H2N2 viruses. Since we sequenced influenza
viruses that were isolated from patients living in geographically
distinct areas in The Netherlands, it is unlikely that all viruses
originated from a single source. Moreover, in the region of the
NP that was sequenced (representing 152 aa) differences were
found between viruses isolated within a single season. Inter-
estingly, the R384G mutation has also been found in influenza
A (H3N2) viruses isolated in Japan after 1993, although viruses
lacking the R384G mutation cocirculated in this area after
1993 (21).
The R384G mutation found in the influenza season 1993–
1994 was accompanied by two other amino acid mutations in
the NP, S259L and E375G. Also, in the Japanese strains con-
taining the R384G mutation (see above) the same accompa-
nying mutations were found, which may indicate a more global
spread of these viruses. The S259L mutation is only 6 aa N
terminal of the HLA-A3 epitope ILRGSVAHK and, there-
fore, could have affected processing of this peptide. However,
our results show that this mutation did not have an effect on
FIG. 1. Maximum likelihood tree based on nucleotide sequences of the NP gene. Part of the NP genes (nt 720 to 1175) of 162 influenza A (H3N2) viruses isolated
from 1989 to 1999 was sequenced and subjected to phylogenetic analysis. Included in the figure are the influenza viruses A/Texas/1/77, A/Memphis/5/80, and
A/Beijing/353/89. The numbers shown in the figure correspond to the numbers shown in Table 1. The insert represents a protein distance tree (Protdist, Fitch) based
on the NP sequence of the representative influenza virus strains. The letter code used for the respective amino acid sequences corresponds to that of Fig. 2.
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FIG. 2. Amino acid sequences of the NP (aa 240 to 391) of influenza A (H3N2) viruses isolated from 1989 to 1999. The consensus sequence of each season is shown
in the upper rows, whereas variant sequences are shown in the lower rows. CTL epitopes are underlined and shown in boldface. Amino acid differences between seasons
are shown in boldface, while differences within a season are shown in boldface italic. All mutations are marked with an arrow. The number in parentheses refers to
the number of isolates showing that sequence.
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MHC class I presentation of the HLA-A3 epitope. Although a
G at position 384 was always accompanied by an L at position
259 and a G at position 375, the latter two amino acids have
previously also been found with an R at position 384, indicating
that the R384G mutation is not forced by the other two mu-
tations or vice versa and that the mutations observed are not
mutually compensatory. In addition, in the influenza season
1989–1990 we obtained a virus isolate having a G at position
375 and an R at position 384 of the NP.
The consequence of a mutation at the anchor residue with
respect to virus escape from immune surveillance by CTLs has
been demonstrated previously (13). The R264K mutation in
the HIV-1 Gag HLA-B27 epitope KRWIILGLNK (263 to
272) was accompanied by progression to AIDS in HIV-1-in-
fected patients who showed strong CTL responses against the
nonmutated epitope. Although the role of CTLs in protection
from influenza virus infection is still controversial, CTLs are
likely to contribute to virus clearance and inhibition of virus
spread (39). Therefore, mutations at the anchor residue of the
influenza A virus NP epitope SRYWAIRTR may have impli-
TABLE 2. Amino acid mutations in the influenza virus NP and the
corresponding nucleotide mutations
Season Amino acid mutation Nucleotide mutation No.a
1989–1990 K293R AAA3AGA 1
T350S ACC3TCC 8
M374I ATG3ATA 1
E375G GAA3GGA 1
R384K AGG3AAG 13
1991–1992 N287S AAT3AGT 4
G290D GGC3GAC 4
1992–1993 S287N AGT3AAT 2
D290G GAC3GGC 2
1993–1994 V299L GTG3TTG 2
R361T AGA3ACA 2
R384G AGG3GGGb 56
1998–1999 R384G AGG3GGGb 15
R389T AGG3ACG 1
a Number of viruses containing the mutation; see also Fig. 2.
b Since all viruses from the influenza season 1993–1994 onwards contained the
R384G mutation, the codon encoding the original R384 in the NP of influenza
viruses of the previous season (1992–1993) was taken for comparison.
FIG. 3. Confirmation of specificity and HLA restriction of CTL clones.
HLA-A3- and -B27-positive (A and B) and HLA-A3- and -B27-negative (C and
D) B-LCL cells were incubated with the HLA-A3-specific peptide ILRGSVAHK
(solid circles) or the HLA-B27-specific peptide SRYWAIRTR (solid triangles)
or left untreated (open circles and open triangles, respectively) followed by
incubation with the NP/A3 (A and C) or NP/B27 (B and D) CTL clone. CTL
assays were performed in triplicate at three E:T ratios. Mean percentages of
specific lysis are shown.
FIG. 4. Effect of mutations in the HLA-B27 epitope on CTL-mediated lysis
of target cells. (A and B) HLA-A3- and -B27-positive B-LCL cells of one donor
were incubated with the HLA-A3-specific peptide ILRGSVAHK (solid circles),
the HLA-B27-specific peptide SRYWAIRTR (solid squares), or the HLA-B27
mutant peptide SGYWAIRTR (open squares) or SKYWAIRTR (open hexa-
gons) or left untreated (open circles) and used as targets in CTL assays with the
NP/A3 (A) or NP/B27 (B) CTL clone as effector. (C and D) The same B-LCL
cells were infected with a control vaccinia virus (open inverted triangles), a
vaccinia virus expressing the NP of A/PR/8/34 (solid triangles), or a vaccinia virus
expressing NP of A/Neth/18/94 (open triangles) followed by incubation with the
NP/A3 (C) or NP/B27 (D) CTL clone. (E and F) Also, B-LCL cells were infected
with influenza virus A/PR/8/34 (solid diamonds), A/Neth/18/94 (open diamonds),
or A/Neth/651/89 (open hexagons) or left untreated (open circles) followed by
incubation with the NP/A3 (E) or NP/B27 (F) CTL clone. CTL assays were
performed in triplicate at three E:T ratios. Mean percentages of specific lysis are
shown.
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cations for HLA-B27-positive influenza virus-infected patients.
At this point, it is not clear what the consequences of the
R384G mutation are with respect to MHC class I binding
and/or recognition by CTLs of the HLA-B8 epitope.
The observation that the R384G mutation was conserved in
all sequenced influenza A (H3N2) viruses isolated after 1993 in
The Netherlands suggests that this mutation is advantageous to
the virus. We did not find differences between a wild-type virus
and an R384G mutant virus with respect to replication prop-
erties in vitro. In addition, in transfection experiments, we have
shown that an RNA molecule that resembles an influenza A
virus gene segment was equally well transcribed and translated
in the presence of wild-type NP and mutant NP. Since the
R384G mutation completely abrogates the recognition of the
HLA-B27 epitope by specific CTLs, influenza A viruses har-
boring this mutation may escape from immunity mediated by
virus-specific CTLs. HLA-B27-positive individuals constitute
approximately 8% of the Caucasian population, which is pre-
dominant in The Netherlands. The immune pressure mediated
by CTLs in these individuals, which recognize the wild-type
HLA-B27 epitope in the NP, may have contributed to the
emergence and continued circulation of escape mutant viruses.
The mutant virus may have emerged from the quasispecies of
influenza viruses in HLA-B27-positive individuals. Since the
R384G mutation did not impose functional constraints on the
NP, a selective pressure in 8% of the individuals may have
been sufficient to drive the selection process. At present, it is
unknown whether the HLA-B27 epitope is immunodominant.
Conceivably, this would favor the emergence of the R384G
mutant virus. Little is known about the in vivo rate of attack of
target cells by specific CTLs: an infected cell may be recog-
nized by one CTL but not by another at the same time, allow-
ing the virus to escape from the action of one CTL clone. Once
having emerged into the human population, viruses with the
R384G mutation are fully replication competent and ulti-
mately have replaced the original virus having the nonmutated
epitope.
In contrast to the HLA-B8 and -B27 epitope, the HLA-A3
epitope proved to be conserved; we found only three silent
mutations out of 162 sequenced influenza A (H3N2) viruses
isolated over 10 years despite a higher prevalence of the
HLA-A3 allele in the human population. With the exception of
one virus having an I265V mutation (41), influenza virus se-
quence database searches (including H1N1, H2N2, and H3N2
viruses isolated over more than 60 years) also did not reveal
amino acid mutations within this epitope. A possible explana-
tion is that mutations in this region of the NP are not tolerated
or are less well tolerated by the virus because of functional
constraints. For example, an R267A mutation in the HLA-A3
epitope has been shown elsewhere to affect RNA binding by
the NP (11). Recently, a second HLA-B27 epitope in the NP
(174 to 184) has been described (16). However, a sequence
database search revealed that this HLA-B27 epitope is com-
pletely conserved.
CTL escape mutants have been shown to arise in individuals
persistently infected with virus, e.g., HIV, as a result of con-
tinuous immune pressure mediated by CTLs. Influenza A vi-
ruses cause acute infections, affecting a large percentage of
individuals each year, and therefore may be considered as
persisting in the human population. We have provided epide-
miological and immunological evidence for antigenic drift in
the influenza A virus NP, possibly as a result of immune pres-
sure mediated by CTLs. Thus, in addition to the introduction
of mutations in the surface glycoproteins allowing escape from
antibody-mediated immunity, the introduction of mutations in
CTL epitopes may be a strategy exploited by influenza A vi-
ruses to escape from CTL-mediated immunity. This would be
the first example of CTL-mediated antigenic drift in a virus
that causes an acute infection.
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